Major global wound care company Acelity is acquiring Crawford Healthcare, a growing UK-based advanced wound care and dermatology company, along with all of its assets. The companies announced the acquisition today, but did not disclose the terms of the agreement.
With the acquisition of Crawford, Acelity expands its portfolio of advanced wound dressings, further strengthening its position as the global leader in advanced wound healing.
Crawford Healthcare develops and commercialises treatments for the care and repair of skin. Crawford’s wound dressing portfolio includes the superabsorbent KerraMax Care range as well as the KerraFoam and KerraCel, in the foam and antimicrobial gelling fibre advanced wound dressings categories, respectively.
Crawford’s advanced wound dressing lines complement Acelity’s existing advanced wound dressings portfolio, which includes the market-leading collagen dressing Promogran Prisma matrix, as well as the Tielle dressing family and Adaptic dressings.
In addition to its commercial products, Acelity will acquire Crawford’s innovative R&D capabilities and manufacturing operations based in Cheshire, UK.
“Crawford’s talented team, highly complementary line of advanced wound dressings, and track record of patient-focused innovation make them a terrific partner to accelerate our global growth,” said R Andrew Eckert, president and CEO of Acelity. “This transaction solidifies our ability to offer the most comprehensive line of wound care solutions and will enable us to create and consolidate leading positions in high-growth market segments; expand and strengthen our customer relationships; and enhance our innovation expertise for the benefit of clinicians and patients around the world.”
Richard Anderson, chief executive of Crawford Healthcare, said: “The rapid growth of the business has been possible due to our focused investment in innovative products which are clinically proven to improve patient outcomes. Becoming part of the world’s largest wound care company will provide us with the scale to optimise our potential within the USA, the largest global market and the ability to further access and grow in other international markets.”
Richard Anderson will continue to lead the Crawford organisation and its products will remain fully available to clinicians and customers as the two companies work together to form integration plans for the remainder of the year.
